A new study aims to delay memory loss before noticeable signs of Alzheimer’s disease begin. The AHEAD Study is an exciting clinical trial investigating the impact of reducing amyloid in the brain.
“The AHEAD Study is accepting participants as young as 55 and starting the investigational treatment earlier than ever before,” said Dr. Reisa Sperling, Professor of Neurology at Harvard Medical School and Director of the Center for Alzheimer’s Research and Treatment at Brigham and Women’s Hospital at Massachusetts General Hospital. “The study features a personalized approach, tailoring dose levels of the investigational treatment based on each participant’s’ level of brain amyloid.”
The AHEAD Study will look at how this study drug may perform in reducing amyloid and preventing cognitive decline in people who have amyloid detected in the brain but have normal memory performance on cognitive tests. Dosing of the investigational treatment in the study will be tailored to the level of amyloid in the brain.
“This is not a study for the faint of heart,” explained Dr. Sperling. “The trial will last for four years and will include once or twice a-month infusions of an investigational treatment or placebo, periodic imaging studies, and memory and thinking tests.”
To qualify for the study, participants need to be 55-80 years old and not have been diagnosed with Alzheimer’s disease or Mild Cognitive Impairment. People 55-64 need to have either a genetic predisposition for Alzheimer’s or a strong family history of the disease. Participants are selected based on the level of amyloid in their brains as determined by imaging tests conducted as part of the study.
The study can provide transportation to and from visits if needed and pays $50 per required visit. There are more than 100 study sites across the world, including 71 in the United States and 4 in Canada.
“We know through our research that changes in the brains of people with Alzheimer’s start as many as 20 years before they notice symptoms like memory problems,” said Dr. Sperling. “Help us get ahead of Alzheimer’s disease by joining the AHEAD Study,” said Dr. Sperling.
Please visit the website (https://www.endalznow.org/studies/ahead-study-multiple-sites) to learn more about the study and to find a location closest to you.